TITLE

Review: Rosiglitazone or pioglitazone as add-on therapy is effective for glycemic control in type 2 diabetes: COMMENTARY

AUTHOR(S)
Home, Philip
PUB. DATE
November 2003
SOURCE
ACP Journal Club;Nov/Dec2003, Vol. 139 Issue 3, p67
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Type 2 diabetes is a progressive condition, which demands a stepped therapeutic approach from lifestyle changes alone, to addition of one or more oral glucose-lowering drugs, to combination with insulin. Peroxisome proliferator-activated receptor-γ agonists, such as rosiglitazone and pioglitazone, have the potential to be true anti-diabetic drugs. These drugs are expensive and it is clear from the review by researchers M. Boucher and colleagues, that they show no advantage in cost-effectiveness over metformin or sulfonylurea monotherapy. Use of these drugs, clinically most effective in people with overt metabolic syndrome, may be an alternative to add-on insulin therapy. Researchers have showed that the introduction of thiazolidinediones can have an important effect on the budget of publicly funded drug programs in Canada.
ACCESSION #
11533501

 

Related Articles

  • Dapagliflozin maintains HR-QOL in diabetes.  // PharmacoEconomics & Outcomes News;10/27/2012, Issue 665, p10 

    The article reports on an international, double-blind clinical trial on the impact of dapagliflozin in health-related quality of life (HR-QOL) of patients with type 2 diabetes.

  • Trusted diabetes drugs. Williams, Gayle // Consumer Reports on Health;Oct2011, Vol. 23 Issue 10, p2 

    The article introduces a report published within the issue that is concerned with the efficacy of several drugs that are used to treat type two diabetes.

  • New oral therapies for type 2 diabetes. Purnell, Jonathan Q.; Hirsch, Irl B. // American Family Physician;11/1/1997, Vol. 56 Issue 7, p1835 

    Provides information on several oral agents for the treatment of type two diabetes available in the United States. Side effects of metformin, acarbose, troglitazone; Its mechanism of action of the drugs; Adverse effects of the drugs.

  • Mims UPDATE.  // GP: General Practitioner;10/6/2003, p62 

    The licensed indications for the antidiabetic agent rosiglitazone have been extended to allow its use as monotherapy in patients with type-2 diabetes mellitus. Its use as monotherapy is particularly for overweight patients inadequately controlled by diet and exercise where metformin is...

  • "Non-inferior" linagliptin could be safer than sulphonylureas.  // BMJ: British Medical Journal (Overseas & Retired Doctors Edition;7/7/2012, Vol. 345 Issue 7864, p15 

    The article reports on a trial by pharmaceutical company Boehringer Ingelheim which found that its new antidiabetic agent, linagliptin, was slightly less effective over two years than the sulphonylurea, glimepiride, and a better safety profile than sulphonylureas.

  • Notice of redundant publication. Porta, Massimo; Pozza, Guido; Lauro, Renato // Acta Diabetologica;Apr2014, Vol. 51 Issue 2, p313 

    A correction to the article "A nomogram to estimate the proportion of patients at haemoglobin A1c target\7 percent with noninsulin antidiabetic drugs in type 2 diabetes: a systematic review of 137 randomized controlled trials" that was published in the January 28, 2012 issue is presented.

  • Review: Rosiglitazone or pioglitazone as add-on therapy is effective for glycemic control in type 2 diabetes.  // ACP Journal Club;Nov/Dec2003, Vol. 139 Issue 3, p67 

    This article discusses whether rosiglitazone or pioglitazone is more effective than other anti-diabetic agents when used either as monotherapy or add-on therapy in patients with type 2 diabetes mellitus. Studies were selected if they were randomized controlled trials comparing rosiglitazone or...

  • Iatrogenic hypogonadism with glucose-lowering therapy? Cummings, Mike // Diabetes Digest;2013, Vol. 12 Issue 3, p128 

    The article discusses the impact of hypogonadism into men with type 2 diabetes (T2D) which may lead to sexual dysfunction. It features several symptoms of the condition including reduced libido, erectile dysfunction and low testosterone levels. It examines the consequences on the used of...

  • Bariatric Surgery Reduces the Need for Glycemic Control Medications and Related Health Care Costs. Pignone, Michael // Clinical Diabetes;Winter2011, Vol. 29 Issue 1, p34 

    The article discusses a study by M. A. Makary and colleagues which was conducted to determine the effect of bariatric surgery on the use of diabetes medications. The results show that bariatric surgery reduces the requirement for glycemic control medications and related health care costs....

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics